WNK1 and cancer: Further supporting the possibility of targeting MYC-dependent cancer cells through WNK1 inhibition, we find evidence in an orthogonal drug repurposing screen (Corsello et al, 2020) that cells with high expression of MYC or dependence on MYC have increased sensitivity to PP121 treatment (Fig 4D).